Pharmaceuticals, Biotechnology and Life Sciences
First Presentation of Data from EV-201 Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Featured in…
Health Canada hasapproved the supplemental New Drug Submission that expands the use ofADCETRIS (brentuximab vedotin) in combination with AVD (Adriamycin,vinblastine and dacarbazine) chemotherapy in patients with previouslyuntreated Stage IV Hodgkin lymphoma (HL).
-ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada Were $135.0 Million in the First Quarter, an Increase of 42…
Immunomedics Inc has concluded a $2 billion worth deal with Seattle based developer of antibody-drug conjugates (ACDs) for treating late stage cancer based on which Seattle Genetics will develop, fund, manufacture and commercialize IMMU-132, Immunomedics’ proprietary solid tumor therapy candidate.